S
Sabarish Ramachandran
Researcher at Texas Tech University Health Sciences Center
Publications - 46
Citations - 1780
Sabarish Ramachandran is an academic researcher from Texas Tech University Health Sciences Center. The author has contributed to research in topics: Cancer & Mammary tumor. The author has an hindex of 17, co-authored 41 publications receiving 1364 citations. Previous affiliations of Sabarish Ramachandran include Georgia Regents University & Keimyung University.
Papers
More filters
Journal ArticleDOI
Amino Acid Transporters in Cancer and Their Relevance to “Glutamine Addiction”: Novel Targets for the Design of a New Class of Anticancer Drugs
TL;DR: Four amino acid transporters have been found to be expressed at high levels in cancer and show promise in development of new tumor-imaging probes and in tumor-specific delivery of appropriately designed chemotherapeutic agents.
Journal ArticleDOI
DNMT1 is essential for mammary and cancer stem cell maintenance and tumorigenesis
Rajneesh Pathania,Sabarish Ramachandran,Selvakumar Elangovan,Ravi Padia,Pengyi Yang,Senthilkumar Cinghu,Rajalakshmi Veeranan-Karmegam,Pachiappan Arjunan,Jaya P. Gnana-Prakasam,Fulzele Sadanand,Lirong Pei,Chang Sheng Chang,Jeong Hyeon Choi,Huidong Shi,Santhakumar Manicassamy,Puttur D. Prasad,Suash Sharma,Vadivel Ganapathy,Raja Jothi,Muthusamy Thangaraju +19 more
TL;DR: An essential role for DNMT1 is uncovered in MaSC and CSC maintenance and theDNMT1-ISL1 axis is identified as a potential therapeutic target for breast cancer treatment.
Journal ArticleDOI
SLC6A14 (ATB0,+) Protein, a Highly Concentrative and Broad Specific Amino Acid Transporter, Is a Novel and Effective Drug Target for Treatment of Estrogen Receptor-positive Breast Cancer
Senthil Karunakaran,Sabarish Ramachandran,Veena Coothankandaswamy,Selvakumar Elangovan,Ellappan Babu,Sudharsan Periyasamy-Thandavan,Ashish Gurav,Jaya P. Gnana-Prakasam,Nagendra Singh,Patricia V. Schoenlein,Puttur D. Prasad,Muthusamy Thangaraju,Vadivel Ganapathy +12 more
TL;DR: It is shown that the transporter is up-regulated specifically in estrogen receptor (ER)-positive breast cancer, demonstrable with primary human breast cancer tissues andhuman breast cancer cell lines, and an effective drug target for the treatment of ER- positive breast cancer.
Journal ArticleDOI
SIRT1 Is Essential for Oncogenic Signaling by Estrogen/Estrogen Receptor α in Breast Cancer
Selvakumar Elangovan,Sabarish Ramachandran,Narayanan Venkatesan,Sudha Ananth,Jaya P. Gnana-Prakasam,Pamela M. Martin,Darren D. Browning,Patricia V. Schoenlein,Puttur D. Prasad,Vadivel Ganapathy,Muthusamy Thangaraju +10 more
TL;DR: SIRT1 inactivation eliminated estrogen/ERα-induced cell growth and tumor development, triggering apoptosis and indicated that SIRT1 is required for estrogen-induced breast cancer growth.
Journal ArticleDOI
Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth
Rajneesh Pathania,Sabarish Ramachandran,G. Mariappan,Priyanka Thakur,Huidong Shi,Jeong Hyeon Choi,Santhakumar Manicassamy,Ravindra Kolhe,Puttur D. Prasad,Suash Sharma,Bal L. Lokeshwar,Vadivel Ganapathy,Muthusamy Thangaraju +12 more
TL;DR: It is suggested that breast CSCs are intrinsically sensitive to genetic and epigenetic modifications and can therefore be significantly affected by epigenetic-based therapies, warranting further investigation of combined DNMT and HDAC inhibition in refractory or drug-resistant breast cancer.